

Review Article

Amir Shamshirian, Keyvan Heydari, Zahra Shams, Amir Reza Aref, Danial Shamshirian*, Omid Reza Tamtaji, Zatollah Asemi, Layla Shojaie, Hamed Mirzaei, Neda Mohammadi, Behdad Zibae, Keyvan Karimifar, Bahman Zarandi, Akbar Hedayatizadeh-Omran and Reza Alizadeh-Navaei*

Breast cancer risk factors in Iran: a systematic review & meta-analysis

<https://doi.org/10.1515/hmbci-2020-0021>

Received April 5, 2020; accepted September 28, 2020;

published online October 21, 2020

Abstract

Objectives: Breast cancer is known as one of the deadliest forms of cancer, and it is increasing globally. There are a variety of proven and controversial risk factors for this malignancy. Herein, we aimed to undertake a systematic review and meta-analysis focus on the epidemiology of breast cancer risk factors in Iran.

Methods: We performed a systematic search via PubMed, Scopus, Web of Science, and Persian databases for identifying studies published on breast cancer risk factors up to March 2019. Meta-analyses were done for risk factors reported in more than one study. We calculated odds ratios (ORs) with corresponding 95% confidence intervals (CIs) using a fixed/random-effects models.

Results: Thirty-nine studies entered into the meta-analysis. Pooling of ORs showed a significant harmful effect for risk factors including family history (OR: 1.80, 95%CI 1.47–2.12), hormonal replacement therapy (HRT) (OR: 5.48, 95%CI

***Corresponding authors:** Reza Alizadeh-Navaei, Gastrointestinal Cancer Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Islamic Republic of Iran, Phone: +98 911 114 7563, E-mail: reza_nava@yahoo.com. <https://orcid.org/0000-0003-0580-000X>; and Danial Shamshirian, Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran, Phone: +98 912 640 6146, E-mail: shamshirian@sbmu.ac.ir. <https://orcid.org/0000-0001-8461-3477>

Amir Shamshirian, Department of Medical Laboratory Sciences, Student Research Committee, School of Allied Medical Science, Mazandaran University of Medical Sciences, Sari, Islamic Republic of Iran; Gastrointestinal Cancer Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Islamic Republic of Iran, E-mail: shamshirian.amir@gmail.com. <https://orcid.org/0000-0002-2735-0209>

Keyvan Heydari, Gastrointestinal Cancer Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Islamic Republic of Iran; Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Islamic Republic of Iran, E-mail: k1heydari96@gmail.com. <https://orcid.org/0000-0002-2843-7832>

Zahra Shams, Department of Cardiology, Cardiovascular Diseases Research Center, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Islamic Republic of Iran, E-mail: zahrashams00@gmail.com

Amir Reza Aref, Department of Medical Oncology, Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA,

E-mail: Amir_aref@hms.harvard.edu. <https://orcid.org/0000-0002-5174-0522>

Omid Reza Tamtaji, Zatollah Asemi and Hamed Mirzaei, Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Islamic Republic of Iran, E-mail: tamtaji.or@gmail.com (O.R. Tamtaji), aseme_r@yahoo.com (Z. Asemi), h.mirzaei2002@gmail.com (H. Mirzaei). <https://orcid.org/0000-0003-2492-3996> (O.R. Tamtaji). <https://orcid.org/0000-0001-5265-4792> (Z. Asemi). <https://orcid.org/0000-0002-9399-8281> (H. Mirzaei)

Layla Shojaie, Department of Medicine, Research Center for Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA, E-mail: Shojaie.layla@gmail.com

Neda Mohammadi, Student Research Committee, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Islamic Republic of Iran, E-mail: neda.mo75@gmail.com

Behdad Zibae, Student Research Committee, School of Medicine, Gonabad University of Medical Sciences, Gonabad, Islamic Republic of Iran, E-mail: Behdad.Zbe73@gmail.com. <https://orcid.org/0000-0001-7021-538X>

Keyvan Karimifar, Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran, E-mail: 13keyvankarimi97@gmail.com

Bahman Zarandi, Student Research Committee, Iran University of Medical Sciences, Tehran, Islamic Republic of Iran, E-mail: Zarandi.bahman@gmail.com

Akbar Hedayatizadeh-Omran, Gastrointestinal Cancer Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Islamic Republic of Iran, E-mail: akbar_hedayati@yahoo.com. <https://orcid.org/0000-0002-9219-883X>

0.84–1.74), passive smokers (OR: 1.68, 95%CI 1.34–2.03), full-term pregnancy at age 30 (OR: 3.41, 95%CI 1.19–5.63), abortion (OR: 1.84, 95%CI 1.35–2.33), sweets consumption (OR: 1.71, 95%CI 1.32–2.11) and genotype Arg/Arg (crude OR: 1.59, 95%CI 1.07–2.10), whereas a significant protective effect for late menarche (OR: 0.58, 95%CI 0.32–0.83), nulliparity (OR: 0.68, 95%CI 0.39–0.96), 13–24 months of breastfeeding (OR: 0.68, 95%CI 0.46–0.90), daily exercise (OR: 0.59, 95%CI 0.44–0.73) and vegetable consumption (crude OR: 0.28, 95%CI 0.10–0.46).

Conclusions: This study suggests that factors such as family history, HRT, passive smokers, late full-term pregnancy, abortion, sweets consumption and genotype Arg/Arg might increase risk of breast cancer development, whereas late menarche, nulliparity, 13–24 months breastfeeding, daily exercise and vegetable consumption had an inverse association with breast cancer development.

Keywords: breast carcinoma; breast tumor; mammary neoplasm; meta-analysis; population at risk.

Introduction

Breast cancer is one of the most common health concerns throughout the world [1–4], which includes 30% of female cancers [5, 6]. It is also known as the second cause of death in developed countries and the third leading cause of death in less developed countries [7–9]. Surprisingly, approximately 502,000 women die due to breast cancer annually [10]. According to the World Health Organization (WHO) prediction, up to 2.3 million women will be diagnosed for breast cancer by 2050 [11, 12].

In Iran, breast cancer has been identified as the most common cancer and also the fifth main cause of death among Iranian women [4, 13]. The standardized incidence rate (ASR) is about 28 per 100,000 people, which has increased in recent years [14]. There are a variety of proven and controversial risk factors for breast cancer. The American Cancer Society has reported that only about a quarter of breast cancers are due to identified risk factors. These factors include aging, urban life, social class (upper-middle class), marital status (single), white race, history of ovarian cancer, early menarche age, late menopause age, history of breast cancer, history of fibrocystic breast disease, family history of breast, uterine and ovarian cancers, and history of radiation exposure. However, it seems that numerous factors have not yet been identified [15].

According to the Iran, aging, history of breast cancer, genetic modification, chest radiation therapy, diethylstilbestrol (DES) intervention, using hormonal replacement

therapy (HRT), low levels of vitamin D, exposure to chemicals in cosmetics, diet, obesity [16], smoking [17], alcohol, fertility and hormonal factors, contraceptives, early menarche, late menopause, high age at first birth, absence of labor history, other malignancies such as ovarian and endometrial carcinoma, are all the most commonly reported risk factors for breast cancer [18, 19].

Considering the incidence and prevalence of breast cancer, the high cost of treatment, risk of involvement in women who are productive in social and socioeconomic settings (>35-year-old) and lack of national screening or early diagnosis, breast cancer is an important subject, the importance of which is reported widely [20–23].

Despite the importance of the associated risk factors with this malignancy, there is no nationwide study in this regard according to our knowledge. Hence, we aimed to undertake a systematic review and meta-analysis focus on the epidemiology of breast cancer risk factors in Iran. We hope our findings could provide a comprehensive report to be useful for future studies.

Method

Search strategy

We followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline for study design, search protocol, screening, and reporting. A systematic search was performed via international databases of PubMed, Scopus, and Web of Science until 05 March 2019. Moreover, for finding Persian papers, we used Google Scholar database and national databases of Scientific Information Database (SID), Iranmedex, and Magiran. The search strategy included MeSH terms and free keywords as follows: ((Breast OR Mammary) AND (Cancer* OR Neoplasm* OR Tumor* OR Malignancy* OR Carcinoma*)) AND (“Risk factor” OR “Risk factors” OR “Population at Risk” OR “Populations at Risk”) AND AND Iran). Persian equivalent words were used for searching in national databases. There was no limitation about the date of publications in our search.

Criteria study selection

Two group members (A.SH and K.HD) selected the papers independently and discussed to solve the disagreements. Studies met the following criteria included in the meta-analysis: (1) comparative studies with a control group such as case-control and cross-sectional; and (2) studies reported the

risk factors of female breast cancer patients in Iran. Studies were excluded if they were: (1) conference abstracts, comments, letters, animal studies, reviews, case reports, and *in vitro* studies; (2) duplicate publications; and (3) included insufficient data for calculating desired parameters.

Data extraction & quality assessment

Two researchers (Z.SH and K.HD) have independently evaluated the quality of studies and extracted data from included papers. The supervisor (R.AN) resolved any disagreements in this part. Data extraction checklist included the name of the first author, publication year, a region of study, number of patients, mean age, quantitative information of risk factors, clinicopathological features, and available correlations.

The Newcastle-Ottawa Scale (NOS) checklist was used to value the selected papers in relation to various aspects of the methodology and study process.

Data analysis

Statistical analysis was performed using STATA v.11 software. To assess the heterogeneities, we used the I-square (I^2) test. According to the studies heterogeneity, we pooled results using a fixed-effects or random-effects model as appropriate for heterogeneity more or less than 50%, respectively.




Figure 1: PRISMA flowchart for study selection process.

Results

Study selection process

Our initial search through databases resulted in 562 papers. After excluding duplicated papers, remained papers screened using title and abstract. Finally, after eligibility assessment of 84 full texts, 41 studies entered into qualitative synthesis, and finally, 39 studies entered into the meta-analysis. PRISMA flow diagram for the study selection process is presented in Figure 1.

Study characteristics

Out of 39 included studies, 35 studies were case-control, and four of them were cross-sectional studies. The studies' sample size ranged from 93 to 25,592, including 54,347 participants. Nine studies were conducted in Tehran province, six in Fars, four in Mazandaran, four in Isfahan, three in East Azerbaijan, two in Guilan, two in Kermanshah, one in West Azerbaijan, one in Golestan, one in Yazd, one in Hormozgan, one in Khuzestan, and one in Razavi Khorasan. Moreover, one study was a joint study between Mazandaran and Guilan, and one study between Tehran and East Azerbaijan. Characteristics of studies entered into meta-analysis presented in Table 1.

Quality assessment

According to quality assessment using the NOS checklist, 39 studies earned the minimum eligibility score and entered into the meta-analysis. It is remarkable that the NOS modified checklist was used for cross-sectional studies [63]. Only one paper was excluded due to a low score. Summary of risk of bias presented in Figure 2. for details, see Supplementary material 2.

Risk factors for breast cancer

According to included studies, over 20 risk factors were reported for breast cancer. The factors reported in only one study, which seems to be rare are as follows: High-fat foods and dairy (e. g. milk, yogurt, and cheese) [62], Fast foods [62], Genital surgery (surgeries related to uterus and ovary such as hysterectomy or oophorectomy) [30, 40], Hopelessness [26], Hair coloring [55], Human papillomavirus infection [37], Epstein-Barr virus infection [64], Ovarian cancer [41], Supplements of selenium, calcium, Vit B12 and Vit D [58].

Table 1: Characteristics of studies entered into the systematic review.

Author, year	Design	Region C/P	No. of participants (Case/Control)	Case Mean age, SD	Control Mean age, SD	Risk factors	Adjusted by
Ebrahimi et al. (2002) [24]	CC	Tehran C	535(286/249)	47.5(12.8)	44.2(13.2)	Age (+), parity (+), FH (+), OCP (-), MeS (+), MaS (+), ES (+), nulliparity (+), AFFTP (+) FH (+)	MeAS, FH, depression and hopelessness
Pesaran et al. (2003) [25]	CC	Isfahan C	352(176/176)	49(11.3)	47(11.4)	Age (=), FH (+), OCP (+), MeS (-), MeAS (-), MaS (*), ES (+), depression (+), Hopelessness (+), quality of life (-), AFFTP (+), anxiety (+), psychiatric medications (+)	MeAS, FH, depression and hopelessness
Montazeri et al. (2004) [26]	CC	Tehran C	729(243/486)	46.6(11.2)	45.5(10.1)	FH (+), PBBD (+), OCP (+), MeS (+), MeAS (+), MaS (+), XE (+), ES (+), parity (+), abortion (-), BF (*)	FH, PBBD, OCP, MeS, MeAS, MaS, XE, ES, abortion, BF
Yavari et al. (2005) [27]	CC	Tehran C	606(303/303)	48.8(9.8)	50.2(11.1)	FH (+), PBBD (+), OCP (+), MeS (+), MeAS (+), MaS (+), XE (+), ES (+), parity (+), abortion (-), BF (*)	FH, PBBD, OCP, MeS, MeAS, MaS, XE, ES, abortion, BF
Mahouri et al. (2007) [28]	CC	Bandar-Abbas C	672(168/504)	48.6(13.7)	48.4(13.6)	FH (+), PBBD (+), OCP (-), MeS (-), MaS (+), MeAS (+), smoking (+), HRT (+), Nulliparity (+), abortion (+), BF (-), AFFTP (+)	FH, PBBD, OCP, MeS, MeAS, MaS, XE, ES, abortion, BF
Naieni et al. (2007) [29]	CC	Mazandaran P	750(250/500)	48.7(11.3)	48(11.4)	FH (+), PBBD (+), OCP (+), MeS (+), MeAS (+), smoking (+), income (=), SS (=), BF (-), parity (-), IM (+), FH (+), OCP (-), MeS (+), MeAS (+), MaS (+), occupation (+), XE (+), PhA (+), ES (+), BMI (+), BF (+), GS (+), TP53 codon 72 polymorphism (+)	Unclear adjustment
Lotfi et al. (2008) [30]	CC	Yazd C	160(80/80)	48.9(9.7)	49.1(9.8)	FH (+), OCP (+), MeAS (-), MaS (+), occupation (+), ES (+), BMI (+), BF (+), GS (+), TP53 codon 72 polymorphism (+)	Occupation, FH
Kazemi et al. (2009) [31]	CC	Rasht & Tonekabon C	102(42/60)				
Ghiasvand et al. (2010) [32]	CC	Shiraz C	1042(521/521)	41.24	41.06	FH (+), OCP (+), MeAS (-), MaS (+), occupation (+), ES (+), BMI (*), AFFTP (*), parity (-), MA (+)	Age, HP, height, weight, BMI, OCP, BF, MeS, MeAS, ES, MaS

Table 1: (continued)

Author, year	Design	Region C/P	No. of participants (Case/Control)	Case Mean age, SD	Control Mean age, SD	Risk factors	Adjusted by
Hajian-tilaki and Kaveh-ahangar (2011) [33]	CC	Babol C	300(100/200)	51.2(9.6)	51.1(9.3)	MeS (-), MeAS (*), AFFTP (+), Parity (-), abortion (+), BF (-)	Parity
Hajian-tilaki (2011) [34]	CC	Babol C	300(100/200)	51.2(9.6)	51.1(9.3)	ES (-)	Re, MeAS, parity, abortion, MeS, BF, OCP, FH, XE, smoking, exercise, BMI
Motie et al. (2011) [35]	CC	Golestan P	267(134/133)	47.15(10.36)	42.96(11.93)	FH (+), XE (*), MaS (+), MeAS (-), PBBD (+), infertility (*)	Unclear adjustment
Ghiasvand et al. (2012) [36]	CC	Shiraz C	986(493/493)	58.2(7.2)	58(7.4)	FH (+), OCP (+), MeAS (+), Occupation (+), ES (+), BMI (*)	Age, Re
Sigaroodi et al. (2012) [37]	CC	Sari C	130(79/51)	47.77(12.55)	34.2(9.7)	Age (-), human papillomavirus (+)	
Ahmadinejad et al. (2013) [38]	CS	Tehran C	728(184/544)		48.6(8.3)	Age (*), MeS (-), MaS (-), smoking (-), Parity (-), AFFTP (+), BMI (-), occupation (+)	MeAS, parity, AFD
Kaviani et al. (2013) [39]	CS	Tehran C	646				Unclear adjustment
Pourzand et al. (2013) [40]	CC	Tabriz C	400(200/200)	50.05(11.47)	49.91(11.83)	GS (+), SS (+)	
Zare et al. (2013) [41]	CC	Tabriz & Tehran	25592(111/25481)	49.18(8.86)	46.65(9.4)	Age (+), FH (+), occupation (+), OCP (-), MeS (+), MaS (*), HRT (+), ES (*), BMI (*), MA (+), SLE (-), SI (*), diet (*)	Age, occupation, ES, BMI, MeS, HRT, OCP
Bidgoli and Azarshab (2014) [42]	CC	Sabzevar C	176(60/116)	36.45(7.02)	34.2(5.7)		
Hosseinzadeh et al. (2014) [43]	CC	Tabriz C	420(140/280)	47.6(10.7)	46.8(10.4)	FH (+), PBBD (+), OCP (+), MeAS (*), MeS (+), MaS (+), smoking (+), PS (+), HRT (+), ES (+), BMI (+), Migration (+), diet (*), nulliparity (+), Abortion (+), BF (-), infertility (+)	MeS, BF, PBBD, MeAS, parity, AFD, abortion, OCP
Mobarakeh et al. (2014) [44]	CC	Tehran C	93(53/40)	40.02(10.01)	39.78(11.21)	BMI (+), diet (*)	Age, BMI, ES

Table 1: (continued)

Author, year	Design	Region C/P	No. of participants (Case/Control)	Case age, Mean age, SD	Control Mean age, SD	Risk factors	Adjusted by
Sepandi (2014) [45]	CC	Shiraz C	11850(197/11653)	49.4(8.7)	40.9(10.5)	FH (+), OCP (+), MeS (+), MeAS (-), MaS (*), occupation (+), ES (-), BMI (+), Nulliparity (*), parity (*), AFFTP (+)	Age, MeAS, AFP, occupation, parity, FH, BF, OCP
Tazhibi et al. (2014) [46]	CC	Isfahan P	257(216/41)			OCP (-), MeS (+), MaS (+), HRT (+)	Occupation, age, MaS, MeS, OCP, HRT
Salarabadi et al. (2015) [47]	CC	Kermanshah C	152(47/105)			Diet (*), SI (+)	
Tajaddini (2015) [48]	CC	Tabriz C	615(306/309)	46.4(10.2)	41.4(9.6)	Diet (*)	Age, MeS, parity, BMI
Veisy et al. (2015) [49]	CC	West Azerbaijan P	194(111/830)	47.6	46.5	OCP (+), MeAS (*), AFFTP (*)	
Ahmadian et al. (2016) [50]	CC	Guilan P	450(225/225)			Diet (*)	
Jafari-Mehdiabad et al. (2016) [51]	CC	Isfahan P	296(98/198)			MaS (+), ES (-), BF (+), income (-)	
Jafarinia et al. (2016) [52]	CC	Dezful C	340(170/170)	45.4(11)	45	FH (+), OCP (*), HRT (+), PhA (*), AFFTP (+), BF (-)	ES, BF, parity, MaS
Montazeri et al. (2016) [53]	CC	Tehran C/Tabriz C	975(432/543)	48.6(4.7)	40.6(10.7)	BF (+), MeAS (-), AFFTP (+)	MeS, AFP, age, BF
Dehghan et al. (2017) [54]	CC	Isfahan P	182(86/96)	52.88(11.92)	40.31(16.82)	Age (+), FH (+)	FH, occupation, MaS, age, MeAS, MeS, HRT, abortion, BMI
Dianatinasab et al. (2017) [55]	CC	Shiraz C	1052(526/526)	47.8(10.58)	46.75(11.08)	FH (+), OCP (+), MeS (+), MaS (+), Smoking (+), PS (+), occupation (+), XE (+), PhA (-), ES (*), hair coloring (+), BMI (+), SQ (*), parity (*), AFFTP (+), BF (*)	MaS, AFD, parity, birth spacing, BF, MeAS
Dianatinasab-2 et al. (2017) [56]	CS	Shiraz C	497			Age (-), FH (+), smoking (-), XE (+), PhA (-), income (-), CD (+)	
Mirfarhadi et al. (2017) [57]	CS	Rasht C	232			FH (+), MaS (+), ES (-), RR (+), IC (+), income (+)	
Vahid et al. (2017) [58]	CC	Tehran C	293(145/148)	49.8(11.8)	48.5(11.9)	SI (-)	Age, BMI, ES, smoking, MeAS, occupation, MeS

Table 1: (continued)

Author, year	Design	Region C/P	No. of participants (Case/Control)	Case Mean age, SD	Control Mean age, SD	Risk factors	Adjusted by
Fararouei et al. (2018) [59]	CC	Shiraz C	1010(505/505)	41.78(10.56)	42.24(10.62)	FH (+), OCP (+), smoking (+), PS (+), occupation (+), PhA (-), ES (+), MA (-), diet (-) TP53 codon 72 polymorphism (+)	Diet, PhA, ES, occupation, PBBBD, OCP, smoking
Pouladi et al. (2018) [60]	CC	Tabriz C	303(143/160)				
Vahid et al. (2018) [61]	CC	Tehran C	293(145/148)	49.83(11.86)	48.54(12)		Age, ES, exercise, BMI, smoking, FH, MeAS, parity, MaS, MeS, OCP, HRT
Marzbani et al. (2019) [62]	CC	Kermanshah C	620(212/408)	41.5(6.2)	39.5(7.1)	Age (+), MaS (-), S (+), BMI (*), Diet (+), RR (+), IC (+), occupation (*)	Age, sex, ES, BMI

(+), risk-increasing; (-), risk-reducing; (=), null; (*), consists of various effects;

C, City; P, Province; CC, Case-control; CS, Cross-sectional; FH, Familial history; OCP, Oral contraceptive pill; MeS, Menopause status; MaS, Marital status; ES, Educational status; AFFP, Age at first full-term pregnancy; HRT, Hormone replacement therapy; SLE, Sunlight exposure; SI, Supplement intake; XE, X-ray exposure; PhA, Physical activity; CD, Chronic diseases; PS, Passive smoker; SQ, Sleep quality; MeAS, Menarche age status; BF, Breastfeeding; IM, Irregular menstruation; PBBBD, Previous benign breast disease; RR, Rural residency; Re, Residence area; IC, Insurance coverage; SS, Socioeconomic status; GS, Genital surgery; OC, Ovary cancer; HP, History of pregnancy; AFD, age at the first delivery; MA, Marriage age.




Figure 2: Risk of bias summary. A: Case-control studies; B: Cross-sectional studies.

Table 2: Summarized pooled ORs of considered risk factors.

Risk factor	Number of studies	I-squared; crude, %	p-Value; crude	OR (95%CI); crude	Number of studies	I-squared; adjusted, %	p-Value; adjusted	OR (95%CI); adjusted
Age	5	94.2	0.000	0.97 (0.92, 1.02)	2	80.6	0.023	1.04 (0.97, 1.11)
Family history	18	24.6	0.165	2.31 (1.95, 2.86)	12	24.3	0.205	1.80 (1.47, 2.12)
Menarche age status								
Unknown categorization	2	89.6	0.002	2.25 (-0.80, 5.30)				
Less than 12 years	5	81.4	0.000	1.31 (0.23, 2.40)				
Between 12 and 15 years	2	54.8	0.137	0.52 (0.26, 0.78)	2	77.3	0.036	0.55 (0.07, 1.03)
Less than 13 years	5	0.0	0.710	1.19 (0.94, 1.44)				
Less than 14 years	5	38.6	0.164	0.91 (0.68, 1.15)				
More than 15 years	5	75.5	0.003	0.81 (0.39, 1.23)	4	35.3	0.201	0.58 (0.32, 0.83)
Body mass index status								
Unknown categorization	3	65.3	0.056	1.02 (1.00, 1.05)	2	77.9	0.034	1.04 (0.99, 1.09)
Between 25 and 29.9	6	0.0	0.699	1.09 (0.91, 1.28)	3	0.0	0.766	1.07 (0.82, 1.32)
More than 30	5	0.0	0.433	1.15 (0.91, 1.39)	3	0.0	0.994	1.21 (0.90, 1.52)
Relationship status								
Single	11	13.6	0.315	0.98 (0.74, 1.23)				
Married	2	0.0	0.678	0.64 (-0.25, 1.54)				
Divorced	7	0.0	0.619	1.15 (0.87, 1.43)				
Education level								
Basic education	14	75.5	0.000	1.23 (0.94, 1.51)	9	87.5	0.000	1.18 (0.70, 1.66)
Academic education	12	71.4	0.000	1.21 (0.80, 1.62)	8	69.8	0.002	0.67 (0.24, 1.10)
Smoking status								
Active smoker	5	63.5	0.027	1.49 (0.89, 2.08)	3	66.3	0.051	1.70 (0.66, 2.74)
Passive smoker	2	0.0	0.657	1.84 (1.43, 2.25)	3	0.0	0.442	1.68 (1.34, 2.03)
Daily exercise	4	73.5	0.010	0.40 (0.05, 0.75)	3	0.0	0.678	0.59 (0.44, 0.73)
Menopausal status	12	88.9	0.000	1.53 (1.06, 1.99)	9	73.9	0.000	1.29 (0.84, 1.74)
Hormone replacement therapy	4	61.9	0.049	1.80 (0.36, 3.23)	3	0.0	0.509	5.48 (2.71, 8.25)
Oral contraceptive	14	80.0	0.000	1.18 (0.93, 1.44)	10	86.9	0.000	1.17 (0.77, 1.57)
Age at first full-term pregnancy								
20–24 years	3	68.0	0.044	1.48 (0.79, 2.17)	2	0.0	0.484	1.92 (1.14, 2.71)
25–29 years	5	0.0	0.560	1.40 (1.00, 1.80)	4	5.3	0.367	1.55 (0.82, 2.29)
30 years	5	0.0	0.758	2.23 (1.45, 3.01)	3	0.0	0.970	3.41 (1.19, 5.63)
Birth giving status								
Nulliparity	6	40.4	0.136	0.77 (0.55, 0.98)	3	28.0	0.249	0.68 (0.39, 0.96)
Abortion	5	86.9	0.000	1.25 (0.57, 1.93)	3	0.0	0.393	1.84 (1.35, 2.33)
Previous benign breast	5	0.0	0.672	1.24 (0.82, 1.67)				
X-ray exposure	5	0.0	0.676	1.42 (1.18, 1.66)	3	83.6	0.002	1.02 (0.19, 1.86)

Table 2: (continued)

Risk factor	Number of studies	I-squared; crude, %	p-Value; crude	OR (95%CI); crude	Number of studies	I-squared; adjusted, %	p-Value; adjusted	OR (95%CI); adjusted
Breastfeeding duration								
Breastfeeding	3	0.0	0.526	0.58 (0.30, 0.85)	2	88.1	0.004	0.73 (0.14, 1.31)
1–12 months	3	40.0	0.189	0.95 (0.41, 1.49)				
13–24 months	4	0.0	0.602	0.57 (0.42, 0.72)	2	0.0	0.624	0.68 (0.46, 0.90)
25–48 months	2	92.1	0.000	1.12 (–0.68, 2.92)	2	0.0	0.402	0.24 (–0.46, 0.94)
More than 49 months					2	0.0	0.410	0.10 (–0.25, 0.44)
Dietary status								
Egg	2	82.7	0.016	0.92 (–0.64, 2.47)				
Fish	2	0.0	0.462	1.47 (0.68, 2.25)				
Sweets	2	73.2	0.053	2.83 (1.38, 4.29)	2	0.0	0.391	2.21 (1.56, 2.87)
Vegetables	3	56.1	0.102	0.28 (0.10, 0.46)				
Genotype status								
Arg/Arg	2	0.0	0.835	1.59 (1.07, 2.10)				
Arg/Pro	2	0.0	0.824	0.69 (0.37, 1.00)				
Genital surgery								
	2	0.0	0.325	2.23 (0.91, 3.55)				
Residency status								
Rural	2	0.0	0.875	1.37 (0.87, 1.86)				

The factors reported in more than one study are as follows: Age, Family history, Menarche age, Body mass index (BMI), Relationship status, Education Level, Smoking status, Daily exercise, Menopausal status, HRT, Oral contraceptive, birth-giving status, Abortion status, Benign Breast Conditions, X-ray exposure, Breastfeeding duration, Dietary status (including sweets, egg, fish, and vegetables), Genotype status and Residency status.

Only clear well-known risk factors reported in two or more studies entered into the meta-analysis.

Individual-related risk factors (Table 2)

Age

Age was considered as a risk factor in four papers. The meta-analysis showed no significant difference between groups for breast cancer occurrence regarding age (OR: 1.04, 95%CI 0.97–1.11). A significant heterogeneity was observed ($I^2=80.6%$, $p=0.023$) (Supplementary material 1).

Family history

Eighteen studies reported on a family history of breast cancer. The meta-analysis between two groups showed that the odds of breast cancer development was 1.80 times

higher in subject with a family history of breast cancer (OR: 1.80, 95%CI 1.47–2.12). A modest heterogeneity was observed ($I^2=24.3%$, $p=0.205$) (Supplementary material 1).

Menarche age

This factor was studied in Nine articles. The meta-analysis showed a significant protective effect for menarche age more than 15 (OR: 0.58, 95%CI 0.32–0.83). Moderate heterogeneity was observed in this regard ($I^2=35.3%$, $p=0.201$) (Supplementary material 1).

Body mass index

BMI was investigated in nine studies. The meta-analysis indicated no significant differences between groups for BMI status (OR: 1.04, 95%CI 0.99–1.09), BMI 25–29.9 (OR: 1.07, 95%CI 0.82–1.32) and BMI more than 30 (OR: 1.21, 95%CI 0.90–1.52) (Supplementary material 1).

Relationship status

Thirteen papers were studied relationship status. The meta-analysis found that there were no significant differences between groups regarding single status (crude OR: 0.98, 95%CI 0.74–1.23), married status (crude OR: 0.64, 95%CI –0.25 to 1.54) and divorced status (crude OR: 1.15, 95%CI 0.87–1.43) (Supplementary material 1).

Education level

This factor was studied in 15 papers. According to meta-analysis, no significant differences were found for both basic education level (OR: 1.18, 95%CI 0.70–1.66) and academic education level (OR: 0.67, 95%CI 0.24–1.10) (Supplementary material 1).

Smoking status

Six papers studied this factor. The meta-analysis showed that the odds of breast cancer occurrence was 1.68 times higher in the passive smokers (OR: 1.68, 95%CI 1.34–2.03). However, no significant relationships were observed for active smokers (OR: 1.70, 95%CI 0.66–2.74) (Supplementary material 1).

Daily exercise

Three studies were included with this factor. The daily exercise showed a protective effect on the occurrence of breast cancer (OR: 0.59, 95%CI 0.44–0.73). No heterogeneity was observed ($I^2=0.0\%$, $p=0.678$) (Supplementary material 1).

Menopausal status

Thirteen studies have investigated this factor. No significant relationships were observed between groups in this regard (OR: 1.29, 95%CI 0.84–1.74). High heterogeneity was observed ($I^2=73.9\%$, $p<0.0001$) (Supplementary material 1).

Hormone replacement therapy

HRT was studied in five papers. The meta-analysis indicated that the odds of breast cancer occurrence was 5.48 time higher in the group with HRT history (OR: 5.48, 95%CI 0.84–1.74). No significant heterogeneity was observed ($I^2=0.0\%$, $p=0.509$) (Supplementary material 1).

Oral contraceptive

A history of OCP intake was discussed in 15 papers. The meta-analysis showed no significant differences between groups in this regard (OR: 1.17, 95%CI 0.77–1.57). High heterogeneity was observed ($I^2=86.9\%$, $p<0.0001$) (Supplementary material 1).

Birth giving status

Age at first full-term pregnancy was considered in six studies. Meta-analysis showed a significant difference for age 20 to 24 (OR: 1.92, 95%CI 1.14–2.71) and age 30 (OR:

3.41, 95%CI 1.19–5.63) in this regard, but no substantial relationships were found for age 25 to 29 (OR: 1.55, 95%CI 0.82–2.29) (Supplementary material 1).

Six studies investigated the relation of nulliparity and chance of breast cancer development. The meta-analysis results indicated that this condition has an inverse relation with the occurrence of breast cancer (OR: 0.68, 95%CI 0.39–0.96) (Supplementary material 1).

Moreover, five papers studied the history of abortion. A significant difference in odds was observed in the meta-analysis of two groups. Subjects with a history of abortion have a higher chance of breast cancer development (OR: 1.84, 95%CI 1.35–2.33). No significant heterogeneity was observed ($I^2=0.0\%$, $p=0.393$) (Supplementary material 1).

Benign breast conditions

Data from five studies were combined for the meta-analysis of benign breast history as a risk factor to develop breast cancer. No significant difference was observed in this regard (crude OR: 1.24, 95%CI 0.82–1.67) (Supplementary material 1).

X-ray exposure

This factor was studied in four papers. No significant differences were observed regarding the history of X-rays exposure between cases and controls (OR: 1.02, 95%CI 0.19–1.86). A significant heterogeneity was observed ($I^2=83.6\%$, $p=0.002$) (Supplementary material 1).

Breastfeeding duration

This factor was investigated in seven studies. The meta-analysis revealed that 13–24 months of breastfeeding has an inverse association with breast cancer occurrence (OR: 0.68, 95%CI 0.46–0.90). No significant heterogeneity was observed ($I^2=0.0\%$, $p=0.624$) (Supplementary material 1).

Dietary status

This factor was studied for egg, fish, sweets, and vegetables. The meta-analysis revealed that egg (crude OR: 0.92, 95%CI –0.64 to 2.47) and fish (crude OR: 1.47, 95%CI 0.68–2.25) do not affect the chance of breast cancer occurrence significantly (Supplementary material 1). However, findings showed that the odds of developing breast cancer were higher in individuals with high sweets consumption (OR: 1.71, 95%CI 1.32–2.11) (Supplementary material 1) and lower

in subjects with regular vegetable consumption (crude OR: 0.28, 95%CI 0.10–0.46) (Supplementary material 1).

Genotype status

Two studies were investigated p53 codon 72 polymorphisms as a breast cancer risk factor. Although genotype Arg/Pro (crude OR: 0.69, 95%CI 0.37–1.00) was not related to the odds of breast cancer development, a significantly higher chance found for genotype Arg/Arg (crude OR: 1.59, 95%CI 1.07–2.10) in this regard (Supplementary material 1).

Genital surgery

Genital surgery was considered in two studies. No significant differences were found regarding the history of genital surgery for breast cancer development (crude OR: 1.37, 95%CI 0.87–1.86) (Supplementary material 1).

Residency status

The place of living was investigated in two studies. The meta-analysis delivered no significant difference between two groups with rural and urban residency status for breast cancer occurrence (crude OR: 1.37, 95%CI 0.87–1.86) (Supplementary material 1).

Discussion

We undertook this systematic review and meta-analysis to identify the risk factors contributing to the occurrence of female breast cancer in Iran. Out of 39 included papers, more than 60 factors were studied as breast cancer risk factors, of which only 27 factors entered the meta-analysis. Out of all risk factors, factors including family history, HRT, passive smokers, late full-term pregnancy, abortion, sweets consumption, and genotype Arg/Arg indicated to be significantly associated with a higher chance of breast cancer development. In contrast, factors of late menarche, nulliparity, 13–24 months of breastfeeding, daily exercise, and vegetable consumption, were demonstrated to be protective. The other remaining risk factors were not associated with the development of breast cancer.

A family history of breast cancer was one of the associated risk factors for breast cancer development in our study. In one of the first meta-analysis on “*Family history and the risk of breast cancer*”, Pharoah et al. [65] pooled estimate of relative risk (RR) indicated that the probability of breast cancer occurrence is higher in those individuals

with a family history of this malignancy (RR: 1.9, 95%CI, 1.7–2.0). They also found that this probability is higher in first-degree relatives, especially mother and sister (RR: 3.6, 95%CI 2.5–5.0). There are many other studies that reported the association of family history with the risk of breast cancer [66–68].

High levels of estrogen can increase the chance of breast cancer development through genotoxic stress induction and breast tissue mutations [69, 70]. Therefore, receiving external estrogen through HRT may increase the risk of breast cancer development. In this regard, HRT users showed the highest chance of developing breast cancer in our meta-analysis (OR: 5.48, 95%CI 0.84–1.74), inconsistent with several studies [71–73]. In contrast, the study of Bae et al. reported no significant association in this regard among Korean Women [74].

In our meta-analysis, although passive smokers were at higher risk of breast cancer development, no significant association was found for active smokers in this case. Our findings were in the same line with the systematic review of Chen et al. [75] among Chinese females, which implied that passive smokers were at higher risk of breast cancer development (OR: 1.62, 95%CI 1.39–1.85), but not active smokers (OR: 1.04, 95%CI 0.89–1.20). Moreover, some other studies reported a significant association between passive smoking and the risk of breast cancer [76–78].

Regarding the age at first full-term pregnancy, our results were in the same line with previous studies, which indicated the increased risk of breast cancer in individuals with late first full-term pregnancy (at age 30 or older) [79, 80]. For nulliparity conditions, our study showed an inverse association with breast cancer development, which was in contrast with several previous reports [81, 82].

Numerous investigators have studied the association of induced abortion and the risk of breast cancer throughout the world. One of the oldest studies titled “*Induced abortion as a cancer risk factor*” discussed the induced abortion as a breast cancer risk factor [83]. Similarly, some meta-analysis also reported the same conclusions [84, 85]. In this regard, our meta-analysis found that induced abortion was significantly associated with the risk of breast cancer in Iranian women. Besides, the study of Deng et al. demonstrated that induced abortion might be related to the risk of breast cancer in parous women (OR: 1.11, 95%CI 1.02–1.20, $p=0.01$), but not in nulliparous women (OR: 1.02, 95%CI 0.86–1.21, $p=0.85$). In contrast, several studies arrived at contradictory conclusions [86, 87].

The meta-analysis findings showed a significant association between sweet foods consumption and the risk of breast cancer. Although we did not find a specific systematic review in this regard, several epidemiological

studies in different regions reported the association of sweet foods consumption and risk of breast cancer [88–91]. For example, Tavani et al. performed a comprehensive case-control study in Italy and found a direct relationship between sweet foods consumption and risk of breast cancer development [91]. In fact, excessive sweets intake with a high glycemic index may cause insulin resistance as well as insulin-related growth factors as promoters of breast carcinogenesis. Moreover, ovarian steroid secretion, including estrogens and androgens, might be stimulated by insulin. Altogether, these processes end up at an increased risk of breast cancer [92, 93].

Previous studies have investigated the relationships of p53 codon 72 polymorphisms and the risk of breast cancer development in different regions [94]. In this investigation, we found that the genotype Arg/Arg is associated with the development of breast cancer, which was inconsistent with the study of Al-Qasem et al. among Saudi women, and in contrast with meta-analysis carried out by Ma et al. and Hou et al. studies [95, 96].

Menarche age does not precisely match with the breast cancer onset. However, they are significantly correlated [97]. This meta-analysis demonstrated an inverse association between late menarche age and risk of breast cancer (OR: 0.58, 95%CI 0.32–0.83). Our findings were in the same direction with two other meta-analyses carried out by Li et al. [98] and Collaborative Group on Hormonal Factors in Breast Cancer [99].

We found that longer breastfeeding duration (13–24 months) plays a protective rule against breast cancer development, inconsistent with numerous meta-analysis in various populations [100–103]. In this regard, according to one of the most comprehensive studies on “*Breast cancer and breastfeeding*” including 47 epidemiological studies in 30 countries, breast cancer development would be reduced by 42%, especially in developing countries because women in these countries usually have a long duration of breastfeeding throughout their lives [104]. In contrast, short breastfeeding duration, which is usual among women in developed countries with small family size, would contribute to a higher risk of breast cancer development in such countries [104].

The updated report “*Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective*” in 2007, recommended physical activity as a protective factor against cancers, especially post-menopausal breast cancer [105]. It was also recommended by the “*American Cancer Society Guidelines on nutrition and physical activity for cancer prevention*” [106]. Our findings also support this hypothesis as a preventive factor for breast cancer devel-

opment. In fact, physical activities affect the risk of cancer development through mechanisms such as metabolic, reproductive effects, hormonal, and immunity enhancement, etc. [107]. The comprehensive study of Moore et al. [108] titled “*Association of Leisure-Time Physical Activity with Risk of 26 Types of Cancer in 1.44 Million Adults*” reported the significant association for high and low physical activity and lower risk of breast cancer (hazard ratio (HR): 0.9, 95%CI 0.87–0.93).

The association between vegetable intake and risk of breast cancer was always controversial. Our results suggest a protective effect of vegetable consumption on the risk of breast cancer. In the same direction, meta-analyses carried out by Liu et al., Woo et al., and Aune et al. indicated a significant association between various types of vegetables and dietary fiber consumption and risk of breast cancer development [109–111]. In contrast, several systematic reviews and meta-analysis showed no significant relationships in this regard [112, 113], and some others were controversial regarding the types of vegetables and their combination intake with fruits as well as breast cancer types [114, 115].

According to the retrospective nature of the included studies, it is recommended to design some longitudinal cohort investigations in order to examine the fundamental role of these risk factors in breast cancer development.

Conclusion

Based on this systematic review and meta-analysis, factors including a family history of breast cancer, HRT, passive smokers, abortion, sweets consumption, and genotype Arg/Arg, play a significant role in the development of breast cancer. In contrast, late menarche, nulliparity, long breastfeeding duration, regular physical activity, and consumption of vegetables showed a significant inverse association with breast cancer occurrence.

Research funding: None.

Author contributions: ASH, RAN, ZSH, and KH designed the study protocol and wrote the manuscript. RAN performed the statistical analysis. ARA, DSH, ORT, ZA, LS, HM, NM, BZ, KK, BZ, and AHO contributed to the study screen, quality assessment, and made critical comments on the manuscript. All authors have read and approved the final manuscript.

Competing interests: The authors declare that they have no competing interests.

Informed consent: Not applicable.

Ethical approval: Not applicable. The protocol of this systematic review and meta-analysis was registered in the International Prospective Register of Systematic Reviews (PROSPERO) with the code CRD42019127382.

References

- Clegg LX, Reichman ME, Miller BA, Hankey BF, Singh GK, Lin YD, et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: national longitudinal mortality study. *Cancer Causes Control* 2009;20:417–35.
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015;136:E359–86.
- Mahboobi A, Alvandi S, Navaei RA. An analytical survey on breast lesions in mammography. *J Babol Univ Med Sci* 2004;6:52–5.
- Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. *Ann Oncol* 2008;20:556–63.
- Dean T, Armando E. Breast cancer. novak. In: Berek J, editor. *Novak's gynecology*, 13th ed. Philadelphia: Lippincott William & Wilkins; 2002.
- Harris J, Lippman M, Morrow M, Osborne C. *Diseases of the breast*, 5th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2014.
- Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, et al. The global burden of cancer 2013. *JAMA Oncol* 2015;1:505–27.
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011;61:69–90.
- Parkin D, Läärä E, Muir C. Estimates of the worldwide frequency of sixteen major cancers in 1980. *Int J Cancer* 1988;41:184–97.
- Izquierdo A, Gispert R, Saladie F, Espinàs JA. Análisis de la incidencia, la supervivencia y la mortalidad según las principales localizaciones tumorales, 1985–2019: cáncer de mama. *Med Clín* 2008;131:50–2.
- Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, et al. The global breast cancer burden: variations in epidemiology and survival. *Clin Breast Cancer* 2005;6:391–401.
- YektaKooshali M, Esmaeilpour-Bandboni M, Sharemi S, Alipour Z. Survival rate and average age of the patients with breast cancer in Iran: systematic review and meta-analysis. *J Babol Univ Med Sci* 2016;18:29–40.
- Akbari M, Abachizadeh K, Khayamzadeh M, Tabatabaee M, Esnaashari F, Motlagh A. Iran cancer report. Tehran, Qom: Cancer Research Center, Shahid Beheshti University of Medical Sciences. Darolfekr; 2008.
- Razi S, Salehiniya H, Dizaji MFL. Epidemiology of prevalent cancer among Iranian women and its incidence trends from 2003–2009 in Iran. *J Arak Univ Med Sci* 2015;18:17–24.
- Kelsey JL, Berkowitz GS. Breast cancer epidemiology. *Cancer Res* 1988;48:5615–23.
- Hajian K, Gholizadehpasha A, Bozorgzadeh SH. Association of obesity and central obesity with breast cancer risk in pre-and post-menopausal women. *J Babol Univ Med Sci* 2013;15:7–15.
- Sani NA, Garan MS, Nasiri MG, Setayesh Y. The effect of active and passive smoking associated with breast cancer. *J Babol Univ Med Sci* 2005;7:63–8.
- Hajizadeh N, Pourhoseingholi M, Emadedin M, Baghestani A, Fazeli Z. Incidence rate of breast cancer in Iranian women, trend analysis from 2003 to 2009. *Int J Pharma Biomed Sci* 2015;4:107–12.
- Yaghmaei S, Hashemi GB, Ghorbani R. Survival rate following treatment of primary breast cancer in Semnan, Iran (1991–2002). *Koomesh* 2008;9:111–6.
- Huo D, Adebamowo C, Ogundiran T, Akang E, Campbell O, Adenipekun A, et al. Parity and breastfeeding are protective against breast cancer in Nigerian women. *Br J Cancer* 2008;98:992.
- Motamed N, Hadi N, Talei A. A Survey on risk factors of breast cancer in women over 35 years of age (Shiraz-2000). *J Adv Med Biomed Res* 2004;12:25–32.
- Naieni KH, Ardalan A, Mahmoodi M, Motevalian A, Yahyapoor Y, Yazdizadeh B. Risk factors of breast cancer in north of Iran: a case-control in Mazandaran Province. *Asian Pac J Cancer Prev* 2007;8:395.
- Peterson NB, Huang Y, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, Anic G, et al. Childbearing recency and modifiers of premenopausal breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 2008;17:3284–7.
- Ebrahimi M, Vahdaninia M, Montazeri A. Risk factors for breast cancer in Iran: a case-control study. *Breast Cancer Res* 2002;4:R10.
- Pesaran Z, Rezaei A, Kia RT, Siydat A. Evaluation of breast cancer risk factors for using in hormone replacement therapy of corticosteroid- treated post-menopausal women. *J Shahrekord Univ Med Sci* 2003;5:70–5.
- Montazeri A, Jarvandi S, Ebrahimi M, Haghghat S, Ansari M. The role of depression in the development of breast cancer: analysis of registry data from a single institute. *Asian Pac J Cancer Prev* 2004;5:316–9.
- Yavari P, Mosavizadeh M, Sadrolhefaz iB, Khodabakhshi R, Madani H, Mehrabi Y. Reproductive characteristics and the risk of breast cancer: a case-control study. *Iran J Epidemiol* 2006;1:11–9.
- Mahouri K, Zahedani MD, Zare S. Breast cancer risk factors in south of Islamic Republic of Iran: a case-control study. *East Mediterr Health J* 2007;13:1265–73.
- Naieni KH, Ardalan A, Mahmoodi M, Motevalian A, Yahyapoor Y, Yazdizadeh B. Risk factors of breast cancer in north of Iran: a case-control in Mazandaran Province. *Asian Pac J Cancer Prev* 2007;8:395–8.
- Lotfi M, Charkhati S, Shobairi S. Breast cancer risk factors in an urban area of Yazd City-Iran, 2006. *Acta Med Iran* 2008;46:258–64.
- Kazemi M, Salehi Z, Chakosari RJ. TP53 codon 72 polymorphism and breast cancer in Northern Iran. *Oncol Res* 2009;18:25–30.
- Ghiasvand R, Maram ES, Tahmasebi S, Tabatabaee SH. Risk factors for breast cancer among young women in Southern Iran. *Int J Cancer* 2010;129:1443–9.
- Hajian-Tilaki KO, Kaveh-Ahangar T. Reproductive factors associated with breast cancer risk in Northern Iran. *Med Oncol* 2011;28:441–6.

34. Hajian-Tilaki K, Kaveh-Ahangar T, Hajian-Tilaki E. Is educational level associated with breast cancer risk in Iranian women?. *Breast Cancer* 2011;19:64–70.
35. Motie MR, Besharat S, Torkjazi R, Shojaa M, Besharat M, Keshtkar A, et al. Modifiable risk of breast cancer in Northeast Iran: hope for the future. A case-control study. *Breast Care* 2011;6:453–6.
36. Ghiasvand R, Bahmanyar S, Zendehtdel K, Tahmasebi S, Talei A, Adami H-O, et al. Post-menopausal breast cancer in Iran; risk factors and their population attributable fractions. *BMC Cancer* 2012;12:414.
37. Sigaroodi A, Nadji SA, Naghshvar F, Nategh R, Emami H, Velayati AA. Human papillomavirus is associated with breast cancer in the north part of Iran. *Sci World J* 2012;2012:837191.
38. Ahmadinejad N, Movahedinia S, Movahedinia S, Naieni KH, Nedjat S. Distribution of breast density in Iranian women and its association with breast cancer risk factors. *Iran Red Crescent Med J* 2013;15:e16615.
39. Kaviani A, Neishaboury M, Mohammadzadeh N, Ansari-Damavandi M, Jamei K. Effects of obesity on presentation of breast cancer, lymph node metastasis and patient survival: a retrospective review. *Asian Pac J Cancer Prev* 2013;14:2225–9.
40. Pourzand A, Farajkhah H, Azhough R, Fakhree MBA. Breast cancer risk factors among women without family history in North West of Iran. *Life Sci J* 2013;10:482–9.
41. Zare N, Haem E, Lankarani KB, Heydari ST, Barooti E. Breast cancer risk factors in a defined population: weighted logistic regression approach for rare events. *J Breast Cancer* 2013;16:214–9.
42. Bidgoli SA, Azarshab H. Role of vitamin D deficiency and lack of sun exposure in the incidence of premenopausal breast cancer: a case control study in Sabzevar, Iran. *Asian Pac J Cancer Prev* 2014;15:3391–6.
43. Hosseinzadeh M, Eivazi Ziaei J, Mahdavi N, Aghajari P, Vahidi M, Fateh A, et al. Risk factors for breast cancer in Iranian women: a hospital-based case-control study in Tabriz, Iran. *J Breast Cancer* 2014;17:236–43.
44. Mobarakeh ZS, Mirzaei K, Hatmi N, Ebrahimi M, Dabiran S, Sotoudeh G. Dietary habits contributing to breast cancer risk among Iranian women. *Asian Pac J Cancer Prev* 2014;15:9543–7.
45. Sepandi M, Akrami M, Tabatabaee H, Rajaeeefard A, Tahmasebi S, Angali KA, et al. Breast cancer risk factors in women participating in a breast screening program: a study on 11,850 Iranian females. *Asian Pac J Cancer Prev* 2014;15:8499–502.
46. Tazhibi M, Dehghani M, Babazadeh S, Makkarian F, Tabatabaieian M, Sadeghi M, et al. Hormonal and reproductive risk factors associated with breast cancer in Isfahan patients. *J Educ Health Promot* 2014;3:69.
47. Salarabadi A, Bidgoli SA, Madani SH. Roles of Kermanshahi oil, animal fat, dietary and non- dietary vitamin D and other nutrients in increased risk of premenopausal breast cancer: a case control study in Kermanshah, Iran. *Asian Pac J Cancer Prev* 2015;16:7473–8.
48. Tajaddini A, Pourzand A, Sanaat Z, Pirouzpanah S. Dietary resistant starch contained foods and breast cancer risk: a case-control study in northwest of Iran. *Asian Pac J Cancer Prev* 2015;16:4185–92.
49. Veisy A, Lotfinejad S, Salehi K, Zhian F. Risk of breast cancer in relation to reproductive factors in North-West of Iran, 2013–2014. *Asian Pac J Cancer Prev* 2015;16:451–5.
50. Ahmadnia Z, Joukar F, Hasavari F, Roushan ZA, Khalili M. Dietary patterns and risk of breast cancer in women in Guilan Province, Iran. *Asian Pac J Cancer Prev* 2016;17:2035–40.
51. Jafari-Mehdiabad F, Savabi-Esfahani M, Mokaryan F, Kazemi A. Relationship between breastfeeding factors and breast cancer in women referred to Seyed Al-Shohada Hospital in Isfahan, Iran. *Iran J Nurs Midwifery Res* 2016;21:622–7.
52. Jafarinia B, Bahadorzai M, Delpisheh A, Sayehmiri K, Tavakoli M. Risk factors of breast cancer in Dezful city of Iran: a case-control study. *Tehran Univ Med J* 2016;74:135–9.
53. Montazeri V, Sadegh FJ, Hosseinpour S, Mirzaei H, Akbari E, Ehsani M, et al. Reproductive risk factors of breast cancer among women in Tehran and northwest of Iran: a case-control study. *Iran J Epidemiol* 2016;12:1–9.
54. Dehghan Z, Sadeghi S, Tabatabaieian H, Ghaedi K, Azadeh M, Fazilati M, et al. ESR1 single nucleotide polymorphism rs1062577 (c.*3804T>A) alters the susceptibility of breast cancer risk in Iranian population. *Gene* 2017;611:9–14.
55. Dianatinasab M, Fararouei M, Mohammadianpanah M, Zare-Bandamiri M, Rezaianzadeh A. Hair coloring, stress, and smoking increase the risk of breast cancer: a case-control study. *Clin Breast Cancer* 2017;17:650–9.
56. Dianatinasab M, Mohammadianpanah M, Daneshi N, Zare-Bandamiri M, Rezaeianzadeh A, Fararouei M. Socioeconomic factors, health behavior, and late-stage diagnosis of breast cancer: considering the impact of delay in diagnosis. *Clin Breast Cancer* 2017;18:239–45.
57. Mirfarhadi N, Ghanbari A, Khalili M, Rahimi A. Predictive factors for diagnosis and treatment delay in Iranian women with breast cancer. *Nurs Midwifery Stud* 2017;6:e27452.
58. Vahid F, Hatami M, Sadeghi M, Ameri F, Faghfoori Z, Davoodi SH. The association between the index of nutritional quality (INQ) and breast cancer and the evaluation of nutrient intake of breast cancer patients: a case-control study. *Nutrition* 2017;45:11–6.
59. Fararouei M, Iqbal A, Rezaian S, Gheibi Z, Dianatinasab A, Shakarami S, et al. Dietary habits and physical activity are associated with the risk of breast cancer among young Iranian women: a case-control study on 1010 premenopausal women. *Clin Breast Cancer* 2018;19:e127–34.
60. Pouladi N, Dehghan R, Feizi MH, Dastmalchi N. Association of P53 (+ 16ins-Arg) haplotype with the increased susceptibility to breast cancer in Iranian-Azeri women. *J Kerman Univ Med Sci* 2018;25:9–17.
61. Vahid F, Shivappa N, Hatami M, Sadeghi M, Ameri F, Naeini YJ, et al. Association between dietary inflammatory index (DII) and risk of breast cancer: a case-control study. *Asian Pac J Cancer Prev* 2018;19:1215–21.
62. Marzbani B, Nazari J, Najafi F, Marzbani B, Shahabadi S, Amini M, et al. Dietary patterns, nutrition, and risk of breast cancer: a case-control study in the west of Iran. *Epidemiol Health* 2019;41:e2019003.
63. Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S, et al. Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis. *PLoS One* 2016;11:e0147601.
64. Aghdam MK, Nadji SA, Khoddami M, Dezfuli HB, Khademi Y. Epstein-barr virus and breast carcinoma in Iran. *Jundishapur J Microbiol* 2017;10:e12800.
65. Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and meta-analysis. *Int J Cancer* 1997;71:800–9.
66. Brewer HR, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Family history and risk of breast cancer: an analysis

- accounting for family structure. *Breast Cancer Res Treat* 2017; 165:193–200.
67. Nindrea RD, Aryandono T, Lazuardi L. Breast cancer risk from modifiable and non-modifiable risk factors among women in Southeast Asia: a meta-analysis. *Asian Pac J Cancer Prev* 2017;18: 3201–6.
 68. Tao P, Hu YY, Huang Y, Li JY. Risk factors of breast cancer in Asian women: a meta-analysis. *Zhonghua liu xing bing xue za zhi=Zhonghua liuxingbingxue zazhi*. 2011;32:164–9.
 69. Germain D. Estrogen carcinogenesis in breast cancer. *Endocrinol Metab Clin North Am* 2011;40:473–84, vii.
 70. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. *N Engl J Med* 2006;354:270–82.
 71. Anothaisintawee T, Wiratkapun C, Lerdstitthichai P, Kasamesup V, Wongwaisayawan S, Srinakaran J, et al. Risk factors of breast cancer: a systematic review and meta-analysis. *Asia Pac J Public Health* 2013;25:368–87.
 72. Chen C-L, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. *J Am Med Assoc* 2002;287:734–41.
 73. Sillero-Arenas M, Delgado-Rodríguez M, Rodrigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. *Obstet Gynecol* 1992;79:2286–94.
 74. Bae JM, Kim EH. Hormone replacement therapy and risk of breast cancer in Korean women: a quantitative systematic review. *J Prev Med Public Health* 2015;48:225–30.
 75. Chen C, Huang YB, Liu XO, Gao Y, Dai HJ, Song FJ, et al. Active and passive smoking with breast cancer risk for Chinese females: a systematic review and meta-analysis. *Chin J Cancer* 2014;33:306–16.
 76. Chen Z, Shao J, Gao X, Li X. Effect of passive smoking on female breast cancer in China: a meta-analysis. *Asia Pac J Public Health* 2015;27:NP58–64.
 77. Johnson KC, Miller AB, Collishaw NE, Palmer JR, Hammond SK, Salmon AG, et al. Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian expert panel on tobacco smoke and breast cancer risk (2009). *Tob Control* 2011;20:e2. <http://dx.doi.org/10.1136/tc.2010.035931>.
 78. Macacu A, Autier P, Boniol M, Boyle P. Active and passive smoking and risk of breast cancer: a meta-analysis. *Breast Cancer Res Treat* 2015;154:213–24.
 79. Albrektsen G, Heuch I, Hansen S, Kvale G. Breast cancer risk by age at birth, time since birth and time intervals between births: exploring interaction effects. *Br J Cancer* 2005;92:167–75.
 80. Ramon JM, Escriba JM, Casas I, Benet J, Iglesias C, Gavalda L, et al. Age at first full-term pregnancy, lactation and parity and risk of breast cancer: a case-control study in Spain. *Eur J Epidemiol* 1996;12:449–53.
 81. Balekouzou A, Yin P, Pamatika CM, Bekolo CE, Nambei SW, Djeintote M, et al. Reproductive risk factors associated with breast cancer in women in Bangui: a case-control study. *BMC Women's Health* 2017;17:14.
 82. Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O'Meara ES, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. *Ann Intern Med* 2012;156:635–48.
 83. Remennick LI. Induced abortion as cancer risk factor: a review of epidemiological evidence. *J Epidemiol Community Health* 1990; 44:259–64.
 84. Brind J, Chinchilli VM, Severs WB, Summy-Long J. Induced abortion as an independent risk factor for breast cancer: a comprehensive review and meta-analysis. *J Epidemiol Community Health* 1996;50:481–96.
 85. Huang Y, Zhang X, Li W, Song F, Dai H, Wang J, et al. A meta-analysis of the association between induced abortion and breast cancer risk among Chinese females. *Cancer Causes Control* 2014; 25:227–36.
 86. Guo J, Huang Y, Yang L, Xie Z, Song S, Yin J, et al. Association between abortion and breast cancer: an updated systematic review and meta-analysis based on prospective studies. *Cancer Causes Control* 2015;26:811–9.
 87. Michels KB, Hsieh CC, Trichopoulos D, Willett WC. Abortion and breast cancer risk in seven countries. *Cancer Causes Control* 1995;6:75–82.
 88. Landa MC, Frago N, Tres A. Diet and the risk of breast cancer in Spain. *Eur J Cancer Prev* 1994;3:313–20.
 89. Lubin JH, Burns PE, Blot WJ, Ziegler RG, Lees AW, Fraumeni JF Jr. Dietary factors and breast cancer risk. *Int J Cancer* 1981;28: 685–9.
 90. Potischman N, Coates RJ, Swanson CA, Carroll RJ, Daling JR, Brogan DR, et al. Increased risk of early-stage breast cancer related to consumption of sweet foods among women less than age 45 in the United States. *Cancer Causes Control* 2002;13: 937–46.
 91. Tavani A, Giordano L, Gallus S, Talamini R, Franceschi S, Giacosa A, et al. Consumption of sweet foods and breast cancer risk in Italy. *Ann Oncol* 2005;17:341–5.
 92. Augustin LS, Dal Maso L, La Vecchia C, Parpinel M, Negri E, Vaccarella S, et al. Dietary glycemic index and glycemic load, and breast cancer risk: a case-control study. *Ann Oncol* 2001;12: 1533–8.
 93. Dobson R. Sweet foods increase breast cancer risk. *BMJ* 2005; 331:1102.
 94. He XF, Su J, Zhang Y, Huang X, Liu Y, Ding DP, et al. Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case-control study. *Breast Cancer Res Treat* 2011;130:517–29.
 95. Hou J, Jiang Y, Tang W, Jia S. p53 codon 72 polymorphism and breast cancer risk: a meta-analysis. *Exp Ther Med* 2013;5: 1397–402.
 96. Ma Y, Yang J, Liu Z, Zhang P, Yang Z, Wang Y, et al. No significant association between the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis of 21 studies involving 24,063 subjects. *Breast Cancer Res Treat* 2011;125:201–5.
 97. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. *Arch Dis Child* 1969;44:291–303.
 98. Li H, Sun X, Miller E, Wang Q, Tao P, Liu L, et al. BMI, reproductive factors, and breast cancer molecular subtypes: a case-control study and meta-analysis. *J Epidemiol* 2017;27:143–51.
 99. Cancer CGoHFIB. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118,964 women with breast cancer from 117 epidemiological studies. *Lancet Oncol* 2012;13:1141–51.
 100. Bernier MO, Plu-Bureau G, Bossard N, Ayzac L, Thalabard JC. Breastfeeding and risk of breast cancer: a meta-analysis of published studies. *Hum Reprod Update* 2000;6:374–86.
 101. Islami F, Liu Y, Jemal A, Zhou J, Weiderpass E, Colditz G, et al. Breastfeeding and breast cancer risk by receptor status—a systematic review and meta-analysis. *Ann Oncol* 2015;26: 2398–407.

102. Unar-Munguia M, Torres-Mejia G, Colchero MA, Gonzalez de Cosio T. Breastfeeding mode and risk of breast cancer: a dose-response meta-analysis. *J Hum Lactation* 2017;33:422–34.
103. Zhou Y, Chen J, Li Q, Huang W, Lan H, Jiang H. Association between breastfeeding and breast cancer risk: evidence from a meta-analysis. *Breastfeed Med* 2015;10:175–82.
104. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease. *Lancet* 2002;360:187–95.
105. Fund WCR, Research AIfC. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Arlington, VA: American Institute for Cancer Research; 2007.
106. Kushi LH, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera EV, et al. American Cancer Society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. *CA Cancer J Clin* 2012;62:30–67.
107. McTiernan A, Ulrich C, Slate S, Potter J. Physical activity and cancer etiology: associations and mechanisms. *Cancer Causes Control* 1998;9:487–509.
108. Moore SC, Lee IM, Weiderpass E, Campbell PT, Sampson JN, Kitahara CM, et al. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. *JAMA Intern Med* 2016;176:816–25.
109. Aune D, Chan DS, Greenwood DC, Vieira AR, Rosenblatt DA, Vieira R, et al. Dietary fiber and breast cancer risk: a systematic review and meta-analysis of prospective studies. *Ann Oncol* 2012;23:1394–402.
110. Liu X, Lv K. Cruciferous vegetables intake is inversely associated with risk of breast cancer: a meta-analysis. *Breast* 2013;22:309–13.
111. Woo HD, Park S, Oh K, Kim HJ, Shin HR, Moon HK, et al. Diet and cancer risk in the Korean population: a meta- analysis. *Asian Pac J Cancer Prev* 2014;15:8509–19.
112. Smith-Warner SA, Spiegelman D, Yaun SS, Adami HO, Beeson WL, van den Brandt PA, et al. Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. *J Am Med Assoc* 2001;285:769–76.
113. van Gils CH, Peeters PH, Bueno-de-Mesquita HB, Boshuizen HC, Lahmann PH, Clavel-Chapelon F, et al. Consumption of vegetables and fruits and risk of breast cancer. *J Am Med Assoc* 2005;293:183–93.
114. Aune D, Chan DS, Vieira AR, Rosenblatt DA, Vieira R, Greenwood DC, et al. Fruits, vegetables and breast cancer risk: a systematic review and meta-analysis of prospective studies. *Breast Cancer Res Treat* 2012;134:479–93.
115. Jung S, Spiegelman D, Baglietto L, Bernstein L, Boggs DA, van den Brandt PA, et al. Fruit and vegetable intake and risk of breast cancer by hormone receptor status. *J Natl Cancer Inst* 2013;105:219–36.

Supplementary Material: The online version of this article offers supplementary material (<https://doi.org/10.1515/hmbci-2020-0021>).